1. Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
- Author
-
Albizua E, Gallardo M, Barrio S, Rapado I, Jimenez A, Ayala R, Rueda D, Sanchez-Espiridion B, Puigdecanet E, Espinet B, Florensa L, Besses C, and Martinez-Lopez J
- Subjects
- Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, Gene Expression Profiling, Gene Expression Regulation drug effects, Humans, Hydroxyurea therapeutic use, Male, Middle Aged, Polycythemia drug therapy, Polycythemia genetics, Polycythemia Vera genetics, Signal Transduction drug effects, Signal Transduction genetics, Thrombocythemia, Essential genetics, Transcription Factors drug effects, Transcription Factors genetics, Young Adult, Gene Expression Regulation, Neoplastic drug effects, Hydroxyurea pharmacology, Janus Kinase 2 genetics, Polycythemia Vera drug therapy, Thrombocythemia, Essential drug therapy, src-Family Kinases genetics
- Abstract
This study investigates the differential gene expression profile of JAK2(V617F)-positive myeloproliferative neoplasm (MPN) patients, with and without response to hydroxyurea (HU) treatment. Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied. Thirty-four genes were overexpressed in patients who did not respond to HU. Of these, some participate in proliferative pathways: MAPK, AKT, Src kinase (SFK), and JAK2 pathway. JAK2 allele burden was similar between groups of responders and nonresponder. A molecular fingerprint distinguishes JAK2(V617F)-positive MPN patients without response to HU treatment, with overexpression of JAK2, MAPK14, PIK3CA, and SFK genes.
- Published
- 2011
- Full Text
- View/download PDF